CA
SIOX

Corriente Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Corriente Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-875,000
Closed -$4.04M – 26
2020
Q3 		$4.04M Buy
+875,000
New +$2.89M 2.05% 12

Other funds holding SIOX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $88.8M AUM 146.47% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Corriente Advisors's SIOX Position: Q4 2020 in Review

Corriente Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2020, closing a stake of 875,000 shares — an estimated $4.04M sold.

Corriente Advisors first reported a position in SIOX in Q3 2020 and held it in 1 quarter. The position peaked at $4.04M in Q3 2020. 62 funds tracked by Wall St. Rank hold SIOX as of Q4 2020.

  • Corriente Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Corriente Advisors sold 875,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2020, an estimated $4.04M.
  • Corriente Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Corriente Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $4.04M in Q3 2020.
  • 62 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2020.

Based on Corriente Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.